Arcus Biosciences, Inc. (RCUS) - What Are Brokerages Thinking About This Stock?

Key Points

• Analysts hold a Moderate Buy consensus on Arcus Biosciences, with 10 buys, three holds and one sell among 14 firms. The average 12-month price target is $38.30, implying upside from the reported $24.37 share price.
• Recent ratings were generally positive: Truist raised its target to $40, while HC Wainwright increased its target to $45; Morgan Stanley maintained a lower $23 target and Weiss Ratings reiterated a sell rating.
• Arcus exceeded quarterly expectations, reporting an adjusted loss of $0.72 per share versus the estimated $0.89 loss and $41 million in revenue, although revenue declined 74.4% year over year and the company remains deeply unprofitable.

Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $38.30.

Several research analysts have issued reports on RCUS shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcus Biosciences in a report on Friday, September 11th. Truist Financial reiterated a "buy" rating and set a $40.00 price target (up from $35.00) on shares of Arcus Biosciences in a research note on Tuesday, September 8th. HC Wainwright upped their price target on shares of Arcus Biosciences from $32.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, July 20th. Morgan Stanley set a $23.00 price target on Arcus Biosciences in a research note on Monday, August 10th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcus Biosciences in a research report on Friday, July 17th.

Insiders Place Their Bets

In related news, CAO Alexander Azoy sold 2,827 shares of Arcus Biosciences stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $30.00, for a total transaction of $84,810.00. Following the completion of the transaction, the chief accounting officer directly owned 39,581 shares of the company's stock, valued at approximately $1,187,430. The trade was a 6.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 7.60% of the company's stock.

Hedge Funds Weigh In On Arcus Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in Arcus Biosciences by 10.0% during the second quarter. GAMMA Investing LLC now owns 3,966 shares of the company's stock valued at $122,000 after purchasing an additional 359 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Arcus Biosciences by 1.7% in the second quarter. Arizona State Retirement System now owns 24,211 shares of the company's stock valued at $746,000 after acquiring an additional 409 shares in the last quarter. Royal Bank of Canada raised its position in shares of Arcus Biosciences by 14.6% during the first quarter. Royal Bank of Canada now owns 4,758 shares of the company's stock valued at $102,000 after buying an additional 607 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in Arcus Biosciences in the 2nd quarter valued at $30,000. Finally, Quantinno Capital Management LP boosted its holdings in shares of Arcus Biosciences by 8.5% during the 1st quarter. Quantinno Capital Management LP now owns 17,295 shares of the company's stock valued at $374,000 after purchasing an additional 1,349 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.

Arcus Biosciences Stock Up 2.3%

Shares of NYSE:RCUS opened at $24.37 on Friday. Arcus Biosciences has a 1 year low of $14.26 and a 1 year high of $31.74. The company has a market cap of $3.10 billion, a PE ratio of -6.25 and a beta of 0.94. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.82 and a quick ratio of 3.82. The stock's 50-day moving average is $27.50 and its 200 day moving average is $26.13.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.89) by $0.17. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The company had revenue of $41.00 million during the quarter, compared to the consensus estimate of $21.98 million. Arcus Biosciences's revenue was down 74.4% on a year-over-year basis. Sell-side analysts anticipate that Arcus Biosciences will post -3.53 EPS for the current year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc is a biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses a proprietary research platform to develop small-molecule and antibody-based therapies designed to target biological mechanisms involved in tumor growth and immune-system regulation.

Arcus' oncology pipeline has included investigational therapies such as zimberelimab, an anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; quemliclustat, a CD73 inhibitor; and etrumadenant, an adenosine receptor antagonist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.